This paper is in the following e-collection/theme issue:

Cancer Survivorship (334) Cancer Prognosis Models and Machine Learning (67) Clinical Cancer Research (116) Innovations and Technology in Cancer Care (531) Lung Cancer (66) Secondary Use of Clinical Data for Research and Surveillance (474)

Published on in Vol 11 (2025)

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/64900, first published .
Impact of Immune Checkpoint Inhibitors on Second Primary Cancer Risk in Patients With Metastatic Lung Cancer Using Real-World Data From the TriNetX Network: Retrospective Cohort Study

Impact of Immune Checkpoint Inhibitors on Second Primary Cancer Risk in Patients With Metastatic Lung Cancer Using Real-World Data From the TriNetX Network: Retrospective Cohort Study

Impact of Immune Checkpoint Inhibitors on Second Primary Cancer Risk in Patients With Metastatic Lung Cancer Using Real-World Data From the TriNetX Network: Retrospective Cohort Study

Authors of this article:

Pierre Heudel1 Author Orcid Image ;   Gema Hernandez2 Author Orcid Image ;   Olivier Denquin2 Author Orcid Image ;   Hugo Crochet1 Author Orcid Image ;   Jean-Yves Blay1 Author Orcid Image
Article Authors Cited by Tweetations (1) Metrics

Pierre Heudel   1 , MD, MSc, LLM ;   Gema Hernandez   2 , MSc ;   Olivier Denquin   2 , MSc ;   Hugo Crochet   1 , MSci ;   Jean-Yves Blay   1 , MD, PhD

1 Medical Oncology Department, Centre Léon Bérard, Lyon, France

2 TriNetX Europe NV, St.Martens-Latem, Belgium

Corresponding Author: